Viatris (VTRS) Tax Provisions (2019 - 2026)
Viatris' (VTRS) quarterly Tax Provisions came in at -$423.7 million in Q1 2026, down 670.36% year-on-year from $74.3 million in Q1 2025, and down 14510.34% quarter-over-quarter from -$2.9 million in Q4 2025.
Viatris (VTRS) Tax Provisions (2019 - 2026) Analysis & Trends
Viatris' Tax Provisions history runs 8 years deep, the most recent figure standing at -$423.7 million for Q1 2026.
- On a quarterly basis, Tax Provisions fell 670.36% year-over-year to -$423.7 million in Q1 2026; TTM through Mar 2026 was -$518.8 million, a 285.15% decrease from a year earlier, with the FY2025 full-year figure at -$150.1 million, down 1464.55% from the prior year.
- Tax Provisions fell to -$423.7 million in Q1 2026 per VTRS's latest filing, from -$2.9 million in the prior quarter.
- Across five years, Tax Provisions topped out at $457.7 million in Q4 2022 and bottomed at -$423.7 million in Q1 2026.
- The 5-year median for Tax Provisions is $69.0 million (2023), against an average of $18.8 million.
- Across the five-year window, Tax Provisions soared 2897.67% in 2025 and slumped 670.36% in 2026, its largest moves.
- Year by year, Tax Provisions stood at $457.7 million in 2022, then slumped by 119.53% to -$89.4 million in 2023, then jumped by 88.81% to -$10.0 million in 2024, then soared by 71.0% to -$2.9 million in 2025, then plunged by 14510.34% to -$423.7 million in 2026.
- Per Business Quant, the three latest VTRS Tax Provisions figures stand at -$423.7 million (Q1 2026), -$2.9 million (Q4 2025), and $120.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 67.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 157.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 676.90 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 43.40 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -423.70 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 48.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 30.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 18.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -423.70 Mn |
| Dec 31, 2025 | -2.90 Mn |
| Sep 30, 2025 | 120.30 Mn |
| Jun 30, 2025 | -212.50 Mn |
| Mar 31, 2025 | -55.00 Mn |
| Dec 31, 2024 | -10.00 Mn |
| Sep 30, 2024 | -4.30 Mn |
| Jun 30, 2024 | -65.40 Mn |
| Mar 31, 2024 | 90.70 Mn |
| Dec 31, 2023 | -89.40 Mn |
| Sep 30, 2023 | 70.60 Mn |
| Jun 30, 2023 | 69.00 Mn |
| Mar 31, 2023 | 98.00 Mn |
| Dec 31, 2022 | 457.70 Mn |
| Sep 30, 2022 | 73.20 Mn |
| Jun 30, 2022 | 75.40 Mn |
| Mar 31, 2022 | 128.30 Mn |
| Dec 31, 2021 | 59.90 Mn |
| Sep 30, 2021 | -111.60 Mn |
| Jun 30, 2021 | 60.10 Mn |